Hemoadsorption in `liver indication'-analysis of 109 patients' data from the cytosorb international registry
peer-reviewed
Erstveröffentlichung
2021-11-05Authors
Ocskay, Klementina
Tomescu, Dana
Faltlhauser, Andreas
Jacob, David
Friesecke, Sigrun
Editor
Vincent, Jean LouisVillar, Jesús
Wissenschaftlicher Artikel
Published in
Journal of Clinical Medicine ; 10 (2021), 21. - Art.-Nr. 5182. - eISSN 2077-0383
Link to original publication
https://dx.doi.org/10.3390/jcm10215182Institutions
UKU. Abteilung KardioanästhesiologieDocument version
published version (publisher's PDF)Abstract
Background: Our aim is to report the results of the ‘liver indication’ subset of patients in the CytoSorb International Registry. Methods: Structured data were recorded. Treatment characteristics and changes from T1 (start of hemoadsorption) to T2 (termination) were evaluated with a special focus on bilirubin, C-reactive protein, procalcitonin, interleukin-6, platelet levels, SOFA scores, mortality, and subjective assessment by the attending physicians. Results: Until January 2021, from the total 1434 patients, 109 (age: 49.2 ± 17.1 years, 57.8% males) received treatment for hyperbilirubinemia. APACHE II-predicted mortality was 49.6 ± 26.8%. In the study, 91% of patients were alive at the termination of hemoadsorption and improvement was observed by the physicians in 75 cases. Overall, 65 (59.6%) patients died in the hospital, and 60 (55.0%) died in the ICU. Patients received a median of two treatments for a median of 43 h (interquartile range: 24–72 h) in total. Serum bilirubin levels reduced significantly to −4.6 (95% CI: −6.329 to −2.8) mg/dL. Thrombocytopenia was reported in four patients as an adverse event. Conclusions: We report the largest case series on hemoadsorption for ‘liver indication’ from the CytoSorb International Registry. The finding of significant bilirubin removal observed in our study could have substantial impact in designing and executing further studies on the effects of hemoadsorption in liver dysfunction, which are certainly warranted.
Subject headings
[GND]: Leberversagen[LCSH]: Liver Failure | Bilirubin
[Free subject headings]: CytoSorb | cytokine adsorption | hemoadsorption | liver support | blood purification
[DDC subject group]: DDC 610 / Medicine & health
Metadata
Show full item recordDOI & citation
Please use this identifier to cite or link to this item: http://dx.doi.org/10.18725/OPARU-45848
Ocskay, Klementina et al. (2022): Hemoadsorption in `liver indication'-analysis of 109 patients' data from the cytosorb international registry. Open Access Repositorium der Universität Ulm und Technischen Hochschule Ulm. http://dx.doi.org/10.18725/OPARU-45848
Citation formatter >